HPM Partners LLC Purchases 225 Shares of Zimmer Biomet Holdings, Inc. (ZBH)
HPM Partners LLC raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,366 shares of the medical equipment provider’s stock after purchasing an additional 225 shares during the quarter. HPM Partners LLC’s holdings in Zimmer Biomet Holdings were worth $1,331,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of ZBH. BlackRock Inc. grew its stake in Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock valued at $2,044,168,000 after purchasing an additional 16,336,262 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Zimmer Biomet Holdings by 92.7% in the second quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock valued at $421,146,000 after purchasing an additional 1,577,874 shares in the last quarter. Harbour Capital Advisors LLC grew its stake in Zimmer Biomet Holdings by 13,131.3% in the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock valued at $10,145,000 after purchasing an additional 1,292,773 shares in the last quarter. Nordea Investment Management AB grew its stake in Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock valued at $602,159,000 after purchasing an additional 987,398 shares in the last quarter. Finally, Glenview Capital Management LLC purchased a new position in Zimmer Biomet Holdings in the first quarter valued at about $94,197,000. Hedge funds and other institutional investors own 85.48% of the company’s stock.
ZBH has been the topic of a number of recent research reports. Goldman Sachs Group, Inc. (The) initiated coverage on Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 target price on the stock. ValuEngine downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Citigroup Inc. boosted their target price on Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, June 9th. Royal Bank Of Canada boosted their target price on Zimmer Biomet Holdings from $133.00 to $140.00 and gave the company an “outperform” rating in a research note on Wednesday, June 21st. Finally, Cantor Fitzgerald initiated coverage on Zimmer Biomet Holdings in a research note on Thursday, June 29th. They issued a “neutral” rating and a $137.00 target price on the stock. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $136.75.
In related news, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/09/hpm-partners-llc-purchases-225-shares-of-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded up 0.03% during trading on Friday, hitting $115.70. The company had a trading volume of 999,596 shares. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.49. The stock has a market capitalization of $23.39 billion, a PE ratio of 32.95 and a beta of 1.21. The stock has a 50-day moving average of $116.64 and a 200-day moving average of $120.78.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter in the previous year, the business posted $2.02 EPS. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s payout ratio is currently 27.59%.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.